SCHEDULE: ARK Investment Management Boosts Pacific Biosciences Stake

ARK Investment Management LLC and Catherine D. Wood have disclosed a 10.30% beneficial ownership stake in Pacific Biosciences of California, Inc.

Summary

• ARK Investment Management LLC and Catherine D. Wood collectively beneficially own 30,924,103 shares of Pacific Biosciences of California, Inc. common stock.
• This represents 10.30% of the class of securities.
• The filing is an Amendment No. 5 to Schedule 13G, indicating an update to previous ownership disclosures.
• ARK Investment Management LLC holds sole voting power over 28,969,023 shares and sole dispositive power over 30,924,103 shares.
• Catherine D. Wood holds shared voting power over 29,599,642 shares and shared dispositive power over 30,924,103 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• ARK Innovation ETF, a series of a Delaware statutory trust, holds an interest in excess of 5% of the securities reported.

Sentiment

Score: 8

Explanation: The continued substantial beneficial ownership by ARK Investment Management and Catherine D. Wood, a prominent investor in disruptive technologies, signals strong confidence in Pacific Biosciences of California, Inc.'s long-term prospects and strategic direction.

Positives

• A significant institutional investor, ARK Investment Management LLC, and its CEO, Catherine D. Wood, maintain a substantial 10.30% stake in Pacific Biosciences, signaling continued confidence in the company's prospects.
• The filing indicates a passive investment strategy, as the shares are held in the ordinary course of business and not for control purposes, which can provide stability to the company's governance.

Future Outlook

NA

Management Comments

• To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing reflects a significant investment by a prominent asset manager known for its focus on disruptive innovation, particularly in sectors like genomics and biotechnology, where Pacific Biosciences operates. ARK's continued substantial stake suggests a belief in the long-term growth potential of the genomics sequencing market and Pacific Biosciences' position within it.

Stakeholder Impact

• Shareholders: The disclosure of a significant, passive institutional stake by ARK Investment Management and Catherine D. Wood may instill confidence and potentially influence other investors' perceptions of the company's value and future prospects.
• Company Management: Awareness of a major institutional holder can influence strategic decisions, though the filing explicitly states the investment is not for control purposes.

Key Dates

Recommendation

The filing indicates that ARK Investment Management LLC and Catherine D. Wood maintain a substantial 10.30% beneficial ownership in Pacific Biosciences of California, Inc. This continued significant stake from a prominent investor in the genomics space suggests a long-term positive outlook on the company's potential. However, as a Schedule 13G filing, it does not provide new operational or financial performance data that would typically drive a change in investment thesis. It primarily confirms a significant institutional position, which generally supports a 'hold' recommendation for existing investors and suggests continued monitoring for potential new investors, awaiting more comprehensive financial or strategic updates.

Keywords

Pacific Biosciences, ARK Investment Management, Catherine D. Wood, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Genomics, Investment Management